암 생검 시장 : 규모, 점유율. 동향 분석, 제품별, 유형별, 용도별, 지역별, 부문 예측(2025-2033년)

Cancer Biopsy Market Summary

The global cancer biopsy market size was estimated at USD 32.32 billion in 2024 and is projected to reach USD 65.68 billion by 2033, growing at a CAGR of 8.3% from 2025 to 2033. The market growth is attributed to the increasing prevalence of cancer, which is propelling the need for innovative diagnostics to provide early and effective diagnostic solutions to patients.

Moreover, the rising awareness of inherited oncology disorders and the rise in genetic testing are further anticipated to drive the growth of the cancer biopsy industry. The National Cancer Institute (NCI) 2022 update highlights that in the U.S. alone, there were approximately 20 million new cases, resulting in deaths of almost 9.7 million cancer-related deaths worldwide. These substantial figures highlight the growing cancer burden and present a significant growth opportunity for the market.

Due to the advantages of liquid biopsy technologies, massive parallel or NGS has emerged as a rapidly growing and evolving technology with increasing applications in various human Products. An increase in alterations of molecules in various types supports the usage of NGS in clinical settings, as it provides a cost- and time-effective way of detecting cancer. Tumor heterogeneity (evaluating different genes at the same time), along with the need for gene profiling, has increased the use of liquid biopsy, which is expected to propel market growth. Moreover, for various applications, such as prostate, breast, non-small-cell lung, colorectal, and ovarian cancer, liquid biopsy is used for diagnostic & screening, making it an important tool.

The increasing incidence of disease is propelling the demand for the diagnosis of cancers at early stages. For instance, as per Global Cancer Statistics 2024, reported by the American Cancer Society, approximately 20 million cancer cases were newly diagnosed in 2022, and 9.7 million people died from it globally. Moreover, the number of cancer cases is predicted to reach 35 million by 2050. When cancer is discovered early and is contained to the organ of origin before it has a chance to spread, survival rates drastically increase, and it is more likely to be effectively cured. Early detection is crucial for lowering cancer-related mortality, especially through efficient screening programs. Early detection increases patient survival rates by 5 to 10 times more than late detection. The 5-year cancer-specific survival rate is only 21% when cancer is discovered after it has spread, as opposed to 89% when it is found early & still localized.

Furthermore, the increasing number of initiatives by various organizations to raise awareness is a major reason for the growing demand for diagnostic products worldwide. Collaborations and partnerships undertaken by CDC, WHO, the National Cervical Cancer Coalition, the U.S. Preventive Services Task Force, & others are expected to drive market growth by increasing cervical cancer screening rates. In addition, major market players are undertaking initiatives to increase awareness about cervical, vulvar, and vaginal cancer, which is likely to encourage people to opt for screening at regular intervals.

For instance, in 2024, India, the U.S., Australia, and Japan launched the Quad Cancer Moonshot Initiative, which was specifically focused on eliminating cervical cancer across the Indo-Pacific region. Similarly, in October 2024, the University of New South Wales (UNSW) Sydney received a donation of USD 25.9 million from the Swire Group. This funding allowed the Kirby Institute at UNSW Sydney to screen 130,000 women in seven Pacific countries, including Fiji, Kiribati, the Republic of Marshall Islands, Samoa, Solomon Islands, Tonga, and Vanuatu, for cervical cancer.

Moreover, awareness among people about early diagnosis and available treatment options and advancements in treatments has substantially improved patient outcomes. According to a Cancer Progress Report published by the American Association for Cancer Research, it was expected that in the U.S., around 2,001,140 new cases of cancer would be diagnosed in 2024, and approximately 611,720 people might die from the Disease.

However, the high cost of diagnostic tests is anticipated to hamper the overall market growth. Diagnostic cancer tests are expensive, increasing the financial burden on families of patients. The government insurance framework is less well-defined in developing countries than in developed countries. Thus, the middle-class patient population who are uninsured cannot afford these tests. In addition, many private insurance players do not cover costs associated with diagnosis in developing countries. As a result, the high cost of diagnosis is limiting the adoption of screening tools, especially in developing countries. However, the scenario is expected to change in the coming years due to booming medical tourism in countries such as India and Malaysia, wherein healthcare treatments & diagnostic solutions are becoming affordable.

Global Cancer Biopsy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer biopsy market report based on product, type, application, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Kits & Consumables
• Services
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Tissue Biopsies
  • Needle Biopsies
  • Surgical Biopsies
• Liquid Biopsies
  • Fine Needle Aspiration (FNA)
  • Core Needle Biopsy (CNB)
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Breast Cancer
• Colorectal Cancer
• Cervical Cancers
• Lung Cancers
• Prostate Cancers
• Skin Cancers
• Blood Cancers
• Kidney Cancers
• Liver Cancers
• Pancreatic Cancers
• Ovarian Cancers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Biopsy Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Cancer Biopsy Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments Market, 2021 - 2033 (USD Million)
• 4.5. Kits and Consumables
  • 4.5.1. Kits and Consumables Market, 2021 - 2033 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. Cancer Biopsy Market: Type Business Analysis

• 5.1. Type Market Share, 2024 & 2033
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 5.4. Tissue Biopsies
  • 5.4.1. Tissue Biopsies Market, 2021 - 2033 (USD Million)
    • 5.4.1.1. Needle Biopsies
      • 5.4.1.1.1. Needle Biopsies Market, 2021 - 2033 (USD Million)
    • 5.4.1.2. Surgical Biopsies
      • 5.4.1.2.1. Surgical Biopsies Market, 2021 - 2033 (USD Million)
• 5.5. Liquid Biopsies
  • 5.5.1. Liquid Biopsies Market, 2021 - 2033 (USD Million)
    • 5.5.1.1. Fine Needle Aspiration (FNA)
      • 5.5.1.1.1. Fine Needle Aspiration (FNA) Market, 2021 - 2033 (USD Million)
    • 5.5.1.2. Core Needle Biopsy (CNB)
      • 5.5.1.2.1. Core Needle Biopsy (CNB) Market, 2021 - 2033 (USD Million)
• 5.6. Others

Chapter 6. Cancer Biopsy Market: Application Business Analysis

• 6.1. Application Market Share, 2024 & 2033
• 6.2. Application Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 6.4. Breast Cancer
  • 6.4.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Colorectal Cancer
  • 6.5.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Cervical Cancers
  • 6.6.1. Cervical Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Lung Cancers
  • 6.7.1. Lung Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Prostate Cancers
  • 6.8.1. Prostate Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Skin Cancers
  • 6.9.1. Skin Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Blood Cancers
  • 6.10.1. Blood Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.11. Kidney Cancers
  • 6.11.1. Kidney Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.12. Liver Cancers
  • 6.12.1. Liver Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.13. Pancreatic Cancers
  • 6.13.1. Pancreatic Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.14. Ovarian Cancers
  • 6.14.1. Ovarian Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.15. Others
  • 6.15.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cancer Biopsy Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Cancer Biopsy Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. U.S. Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Canada Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Mexico Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. UK Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Germany Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. France Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Italy Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Spain Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Denmark Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Sweden Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Norway Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Japan Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. China Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. India Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Australia Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. South Korea Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Thailand Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Japan Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. China Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. South Africa Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Saudi Arabia Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. UAE Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Kuwait Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. QIAGEN
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Illumina, Inc.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. ANGLE plc
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. BD (Becton, Dickinson and Company)
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Myriad Genetics, Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Hologic, Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Biocept, Inc.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Thermo Fisher Scientific, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Danaher
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. F. Hoffmann-La Roche Ltd.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Lucence Health Inc.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. GRAIL, Inc.
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic Initiatives
  • 8.5.13. Guardant Health Inc.
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial Performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic Initiatives
  • 8.5.14. Exact Sciences Corporation
    • 8.5.14.1. Overview
    • 8.5.14.2. Financial Performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic Initiatives
  • 8.5.15. Freenome Holdings, Inc.
    • 8.5.15.1. Overview
    • 8.5.15.2. Financial Performance
    • 8.5.15.3. Product Benchmarking
    • 8.5.15.4. Strategic Initiatives
  • 8.5.16. Biodesix (Integrated Diagnostics)
    • 8.5.16.1. Overview
    • 8.5.16.2. Financial Performance
    • 8.5.16.3. Product Benchmarking
    • 8.5.16.4. Strategic Initiatives
  • 8.5.17. Oncimmune
    • 8.5.17.1. Overview
    • 8.5.17.2. Financial Performance
    • 8.5.17.3. Product Benchmarking
    • 8.5.17.4. Strategic Initiatives
  • 8.5.18. Epigenomics AG
    • 8.5.18.1. Overview
    • 8.5.18.2. Financial Performance
    • 8.5.18.3. Product Benchmarking
    • 8.5.18.4. Strategic Initiatives
  • 8.5.19. HelioHealth (Laboratory for Advanced Medicine)
    • 8.5.19.1. Overview
    • 8.5.19.2. Financial Performance
    • 8.5.19.3. Product Benchmarking
    • 8.5.19.4. Strategic Initiatives
  • 8.5.20. Genesystems, Inc. (Genesys Biolabs)
    • 8.5.20.1. Overview
    • 8.5.20.2. Financial Performance
    • 8.5.20.3. Product Benchmarking
    • 8.5.20.4. Strategic Initiatives
  • 8.5.21. Chronix Biomedical, Inc.
    • 8.5.21.1. Overview
    • 8.5.21.2. Financial Performance
    • 8.5.21.3. Product Benchmarking
    • 8.5.21.4. Strategic Initiatives
  • 8.5.22. Personal Genome Diagnostics Inc.
    • 8.5.22.1. Overview
    • 8.5.22.2. Financial Performance
    • 8.5.22.3. Product Benchmarking
    • 8.5.22.4. Strategic Initiatives
  • 8.5.23. Natera, Inc.
    • 8.5.23.1. Overview
    • 8.5.23.2. Financial Performance
    • 8.5.23.3. Product Benchmarking
    • 8.5.23.4. Strategic Initiatives
  • 8.5.24. Personalis Inc.
    • 8.5.24.1. Overview
    • 8.5.24.2. Financial Performance
    • 8.5.24.3. Product Benchmarking
    • 8.5.24.4. Strategic Initiatives